REGN
Price
$807.48
Change
+$25.44 (+3.25%)
Updated
Oct 20 closing price
Capitalization
83.13B
10 days until earnings call
Intraday BUY SELL Signals
SLXN
Price
$0.15
Change
-$0.00 (-0.00%)
Updated
Oct 20 closing price
Capitalization
855.17K
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REGN vs SLXN

REGN vs SLXN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
REGN vs. SLXN commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and SLXN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for REGN with price predictions
Oct 19, 2026

REGN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for REGN turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Indicator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 57 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

Following a +5.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 207 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

REGN moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for REGN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

REGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.622) is normal, around the industry mean (2.978). P/E Ratio (19.285) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.005) settles around the average of (134.267) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for SLXN with price predictions
Oct 20, 2026

SLXN in -4.04% downward trend, sliding for three consecutive days on October 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLXN declined for three days, in 184 of 201 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLXN as a result. In 28 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 42%.

The Aroon Indicator for SLXN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +43.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLXN advanced for three days, in 53 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

SLXN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.436) is normal, around the industry mean (3.009). P/E Ratio (-0.008) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. SLXN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
REGN: Fundamental Ratings
REGN
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
86
SMR RATING
1..100
59
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
16
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
REGNSLXN
RSI
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
61%
Bullish Trend 1 day ago
62%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 1 day ago
42%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
65%
Bullish Trend about 1 month ago
56%
Declines
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (REGN: $807.48 vs. SLXN: $0.15)
Brand notoriety: REGN: Notable vs. SLXN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 82% vs. SLXN: 24%
Market capitalization -- REGN: $83.13B vs. SLXN: $855.17K
REGN [@Biotechnology] is valued at $83.13B. SLXN’s [@Biotechnology] market capitalization is $855.17K. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 1 FA rating(s) are green while SLXN’s FA Score has 0 green FA rating(s).

  • REGN’s FA Score: 1 green, 4 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, REGN is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 4 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).

  • REGN’s TA Score: 4 bullish, 6 bearish.
  • SLXN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SLXN is a better buy in the short-term than REGN.

Price Growth

REGN (@Biotechnology) experienced а +7.22% price change this week, while SLXN (@Biotechnology) price change was -12.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.

Reported Earning Dates

REGN is expected to report earnings on Oct 30, 2026.

SLXN is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
REGN
Daily Signal:
Gain/Loss:
SLXN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DFH9.590.94
+10.87%
Dream Finders Homes
GTBP7.310.62
+9.27%
GT Biopharma Inc
DTIL6.560.37
+5.98%
Precision BioSciences
CTSH68.181.39
+2.08%
Cognizant Technology Solutions Corp
ABCL11.71-0.22
-1.84%
AbCellera Biologics

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+3.25%
VRTX - REGN
43%
Loosely correlated
+2.53%
RPRX - REGN
36%
Loosely correlated
+3.29%
BMRN - REGN
36%
Loosely correlated
+3.24%
ARQT - REGN
36%
Loosely correlated
+2.92%
INCY - REGN
33%
Loosely correlated
+2.97%
More